Results 101 to 110 of about 3,251 (194)

The Prognostic Significance of Handgrip Strength in Cirrhosis: Simplicity Is the Ultimate Sophistication

Portal Hypertension &Cirrhosis, EarlyView.
The advantages to measure handgrip strength (HGS) are simple, convenient, noninvasive, cost‐effective, and easy to be widely carried out during daily clinical practice. Mounting evidence demonstrates that muscle strength measured by HGS is a feasible and reliable metric to evaluate nutritional status, as well as relevant cirrhosis‐related complications
Binxin Cui, Ziyi Yang, Chao Sun
wiley   +1 more source

The Role of Magnesium in Liver Cirrhosis

Portal Hypertension &Cirrhosis, EarlyView.
Magnesium is a vital mineral involved in over 300 enzymatic reactions, crucial for physiological functions. Its deficiency, common in liver cirrhosis patients, correlates with poor outcomes by affecting inflammation, oxidative stress, fibrosis, and immunity. This review explores magnesium's role in cirrhosis and its interaction with disease mechanisms.
Weiye Zeng, Xudan Wang, He Qi, Hongtao Tang, Xun Qi   +4 more
wiley   +1 more source

Pharmacotherapy for Cirrhosis in Japan

Portal Hypertension &Cirrhosis, EarlyView.
As cirrhosis progresses from the compensated to the decompensated stage, liver disease‐related events such as varices, ascites, encephalopathy, sarcopenia, jaundice, and bleeding tendency, as well as liver carcinogenesis, can occur at a high rate. With the advent of new pharmacotherapies for cirrhosis in the last decade, liver fibrosis has been shown ...
Hiroki Nishikawa, Soo Ki Kim, Akira Asai
wiley   +1 more source

Model‐Based Meta‐Analysis of the Relationship Between Pioglitazone and Histological Outcomes in Metabolic Dysfunction‐Associated Steatohepatitis Patients

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Given the high prevalence of the population who have metabolic dysfunction‐associated steatohepatitis (MASH), interest is growing in MASH‐targeted treatments. However, currently, there has been only one regulatory approved drug for MASH (Rezdiffra).
Quyen Thi Tran, Tham Thi Bui, Lien Thi Ngo, Bo Ram Yang, In‐Hwan Baek, Van Hung Nguyen, Kyung Ae Lee, Hwi‐yeol Yun, Jung‐woo Chae, Soyoung Lee, Jae Hyun Kim, Woojin Jung   +11 more
wiley   +1 more source

A New Classification System for Fatty Liver—What Sonographers Should Know

Sonography, EarlyView.
ABSTRACT Hepatic steatosis or fatty liver disease is a rapidly emerging health issue and is closely linked to an increase in cardiometabolic conditions such as obesity and type 2 diabetes. The nomenclature surrounding fatty liver has recently undergone multiple reviews to better reflect its underlying causes.
Elspeth L. Keys, Katie L. McMahon, Elizabeth Powell, Heather Allen, Christopher Edwards   +4 more
wiley   +1 more source

Multiple Concomitant Precipitating Factors of Hepatic Encephalopathy Are Associated With a Poor Prognosis in Patients With Cirrhosis Admitted to Intensive Care Unit

United European Gastroenterology Journal, EarlyView.
ABSTRACT Introduction Management of hepatic encephalopathy relies on the identification and control of precipitating factors (PF). The prognostic value of a PF is unknown, which we aimed to explore. Patients and Methods Single‐center retrospective study of cirrhotic patients included in a prospective cohort admitted to an intensive care unit (ICU ...
Marika Rudler, Marie de Matharel, Charlotte Bouzbib, Sarah Mouri, Lyes Kheloufi, Nicolas Weiss, Philippe Sultanik, Dominique Thabut   +7 more
wiley   +1 more source

CiThroModel Improves Prediction of Symptomatic Venous Thromboembolism in Hospitalized Patients With Cirrhosis Without Hepatocellular Carcinoma

United European Gastroenterology Journal, EarlyView.
ABSTRACT Background & Aims Venous thromboembolism (VTE) is a recognized complication of acutely ill patients, but its incidence and risk factors in those with cirrhosis are uncertain. Methods We retrospectively studied a consecutive cohort of cirrhosis patients non‐electively admitted to our medical unit to determine the rates of symptomatic VTE during
Alberto Zanetto, Alessandro Vitale, Filippo Pelizzaro, Vittorio Simeon, Elena Campello, Laura Turco, Lorenz Balcar, Francesco Paolo Russo, Patrizia Burra, Paolo Simioni, Marco Senzolo   +10 more
wiley   +1 more source

Rifaximin‐α in Patients With Recurrent Episodes of Hepatic Encephalopathy Due to Cirrhosis Reduces Healthcare Utilization

United European Gastroenterology Journal, EarlyView.
ABSTRACT Background and Aims Hepatic encephalopathy is a frequent complication of cirrhosis. Rifaximin‐α has been included in guidelines for secondary prevention of hepatic encephalopathy, but there are few real‐world data on its efficacy and impact on healthcare utilization.
Diederick J. van Doorn, Kirsi. M. A. van Eekhout, Koos de Wit, L. C. Baak, Michael Klemt‐Kropp, Bart J. Verwer, Philip Friederich, Gijs J. de Bruin, Xander G. Vos, Joost P. H. Drenth, R. Bart Takkenberg   +10 more
wiley   +1 more source

Postoperative TIPS Reaction in a Patient With Portal Vein Dysfunction

Portal Hypertension &Cirrhosis, EarlyView.
Qihao Du, Jiaming Lan, Ke Xu, Meng Niu
wiley   +1 more source

Diagnosis and Monitoring Pathways Using Non‐Invasive Tests in Patients With Alpha‐1 Antitrypsin Deficiency‐Associated Liver Disease: Results From an Expert Delphi Panel

United European Gastroenterology Journal, EarlyView.
ABSTRACT Background and Aims The severe alpha‐1 antitrypsin deficiency (AATD) genotype Pi*ZZ increases the risk of liver disease (AATD‐LD) and lung disease. While non‐invasive tests (NITs) are widely used for fibrosis stage and monitoring of all liver diseases, the consensus for use in AATD‐LD is limited.
Virginia C. Clark, Mark A. Price, Jon Russo, Rohit Loomba, Alice M. Turner, Pavel Strnad   +5 more
wiley   +1 more source